Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Key Highlights
- ➤PH-762 commercial-scale cGMP drug substance batch successfully released
- ➤Validated drug substance advances to final drug product completion
- ➤Phase 2b clinical study expected to initiate in first quarter 2027
- ➤Manufacturing milestone supports supply chain readiness and reduces development risks
Expert Statements
Robert Bitterman, President and CEO of Phio Pharmaceuticals
“This achievement culminates a complex coordination and cross functional execution process started some 16 months ago among numerous highly skilled scientists and engineers.”
Robert Bitterman, President and CEO of Phio Pharmaceuticals
“This is a meaningful advancement in the PH-762 program, mitigating key development and manufacturing risks, and positions the Company to execute on important upcoming clinical and regulatory milestones.”
Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), representing a critical operational and strategic milestone as the Company advances PH-762 to the next stage of clinical development.
Get started
Create a free account to read the full story.